Ara-290 (cibinetide) ARA-290
Erythropoietin-derived innate repair receptor agonist studied in phase 2; not approved anywhere.
Monograph plannedAll content is for general information only — not medical advice, not a dosing or usage recommendation, and not a claim of efficacy. Many substances are not approved as medicines or are prescription-only; whether possession and use are legal depends on the law of your country of residence and is your own responsibility. myPeptides does not sell or supply any substances — it is an information and organization tool. For health questions, consult a licensed physician or pharmacist.
Every peptide covered here, with its mechanism class, legal status and WADA status. This is a status register, not a shop: no suppliers, no doses, no efficacy claims.
5 of 73
Erythropoietin-derived innate repair receptor agonist studied in phase 2; not approved anywhere.
Monograph plannedSynthetic pentadecapeptide studied mainly in animal models; no approval anywhere.
Australia: Schedule 4
MonographTripeptide fragment of alpha-melanocyte-stimulating hormone; preclinical only, no approval.
MonographHuman cathelicidin antimicrobial peptide studied in phase 2 wound trials; not approved anywhere.
MonographSynthetic peptide linked to the thymosin beta-4 sequence; no approval in any market.
MonographTrack doses, plans and progress on your phone — end-to-end encrypted.
This article is for informational purposes only and does not replace medical advice. myPeptides gives no dosing recommendations.